BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BEAM-302 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BEAM-302\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06389877-10771@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:BEAM-302: Phase 1/2 readout est. (NCT06389877)
DESCRIPTION:BEAM-302\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients 
 With Alpha-1 Antitrypsin Deficiency (AATD)\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beam-302#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063898
 77
URL:https://assetmemo.bio/drug/beam-302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
